- Home
- RCMT vs BDTX Comparison
RCMT vs BDTX Comparison
Compare RCMT & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RCMT | BDTX |
|---|---|---|
| Founded | 1971 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.0M | 116.8M |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RCMT | BDTX |
|---|---|---|
| Price | $19.82 | $2.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $30.00 | $10.40 |
| AVG Volume (30 Days) | 40.7K | ★ 573.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.45 |
| EPS | ★ 1.34 | 0.65 |
| Revenue | ★ $186,737,000.00 | N/A |
| Revenue This Year | $16.29 | N/A |
| Revenue Next Year | $6.92 | N/A |
| P/E Ratio | $14.63 | ★ $3.48 |
| Revenue Growth | ★ 5.83 | N/A |
| 52 Week Low | $13.20 | $1.20 |
| 52 Week High | $28.19 | $4.94 |
Technical Indicators
Market Signals| Indicator | RCMT | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.06 | 45.05 |
| Support Level | $19.35 | $2.19 |
| Resistance Level | $21.00 | $2.67 |
| Average True Range (ATR) | 0.70 | 0.14 |
| MACD | 0.16 | -0.01 |
| Stochastic Oscillator | 71.54 | 43.66 |
Price Performance
Historical ComparisonAbout RCMT RCM Technologies Inc.
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.